Home ›
Sarcoma Trials ›
NCT07633756
A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy
To learn if the study drug REC-617 can help to control LMS. The safety of REC-617 will also be studied.
Trial Details
NCT ID NCT07633756
Phase PHASE1
Sponsor M.D. Anderson Cancer Center
Status RECRUITING
Cancer Type Sarcoma
Interventions
Locations (sample) Houston, Texas, United States|29.76328,-95.36327
Key Eligibility Criteria
Eligibility Criteria A. Disease Characteristics Histologically confirmed leiomyosarcoma (any site of origin). RB1-negative tumor, as assessed by immunohistochemistry (IHC) with a cutoff of 0% versus any expression Participants will have measurable diseases … Participant will have tumor lesion(s) or metastases amenable to biopsy, excluding bone metastases, as confirmed by a radiologist, if appropriate, a…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Sarcoma Trials on Trialify →